Hanta Virus In India : Epidemiology, Clinical Evidence, Surveillance Gaps, and Pharma Leadership Imperatives

In April-May 2026, the world's attention turned to an unassuming Dutch cruise ship, the MV Hondius, anchored off Praia, Cape Verde. This vessel became the centre of a rare and alarming hantavirus outbreak that rattled international health authorities and reignited scientific conversation about this deadly rodent-borne pathogen.

On 2 May 2026, the World Health Organization (WHO) received a formal notification from the United Kingdom's National IHR Focal Point about a cluster of severe acute respiratory illness on board, including two deaths and one critically ill passenger. Laboratory testing in South Africa subsequently confirmed hantavirus infection in at least two passengers, with the Andes strain identified as the causative agent.

As of 7 May 2026, WHO Director-General Dr. Tedros Adhanom Ghebreyesus briefed international media: 

"Eight cases have been reported so far, including three deaths. Five of the eight cases have been confirmed as hantavirus." — Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, May 7, 2026

The index cases were Dutch nationals who had travelled through Argentina, Chile, and Uruguay before boarding the ship on 1 April 2026. The Andes virus, indigenous to the Southern Cone of South America, is the only known hantavirus strain capable of limited human-to-human transmission, a characteristic that makes it uniquely worrisome for global public health officials.

Health officials across more than 12 countries, including the UK, USA, Germany, Netherlands, Switzerland, South Africa, Spain, and France, initiated contact-tracing for the approximately 40 passengers who had disembarked before the outbreak was identified. While India has not reported any confirmed cases linked to this 2026 international cluster, the episode serves as a powerful wake-up call for India's pharma leadership and public health institutions.

Understanding Hantavirus: Biology, Transmission, and Global Burden

Hantaviruses are a genus of single-stranded, tri-segmented RNA viruses within the family Hantaviridae, order Bunyavirales. They are maintained in nature through persistent, asymptomatic infection in specific rodent reservoir hosts and are transmitted to humans primarily via inhalation of aerosolized rodent excreta (urine, faeces, saliva).

Human hantavirus disease manifests in two principal clinical syndromes: Hemorrhagic Fever with Renal Syndrome (HFRS), caused predominantly by Old World strains (Hantaan, Seoul, Puumala, Dobrava), and Hantavirus Pulmonary Syndrome (HPS), caused by New World strains (Sin Nombre, Andes, Black Creek Canal). The case fatality rate ranges from <1% to 15% in Asia and Europe, and can reach 50% in the Americas.

"Hantavirus infections are relatively uncommon globally, but their high case fatality rate and potential for rapid progression demand immediate clinical vigilance and robust surveillance infrastructure." — WHO Disease Outbreak News, May 2026

Key epidemiological data from the WHO underscores the global burden:

• Americas (2025, as of Epi Week 47): 229 cases and 59 deaths across 8 countries; CFR of 25.7%.
• European Region (2023): 1,885 cases (0.4 per 100,000), the lowest rate observed from 2019 to 2023.
• East Asia (annual): Over 10,000 HFRS cases; declining incidence in China and South Korea over recent decades.

Global epidemiology highlights:

Source: WHO Disease Outbreak News, May 2026; WHO Fact Sheets on Hantavirus; Frontiers in Microbiology, 2023.

Hantavirus in India: The Evidence So Far

India's encounter with hantavirus is not a recent phenomenon. The story begins in 1964 when the Thottapalayam virus (TPMV) was first isolated at the Christian Medical College (CMC), Vellore, Tamil Nadu, from a Suncus murinus (Asian House Shrew) by Carey et al. TPMV is now recognized as the oldest known hantavirus and, critically, the only hantavirus strain indigenous to the Indian subcontinent.

Decades later, a landmark pilot study by Chandy et al. (2005), published in the Indian Journal of Medical Research, conducted serological screening of 347 patients with acute febrile illness in South India. A striking 5.2% of patients showed serological evidence of hantavirus infection, with sequences related to the Hantaan virus. This was among the first robust evidence that hantaviruses were actively circulating in human populations in India, not merely harboured in animal reservoirs.

Documented Case Reports and Clinical Evidence

The first formally documented Indian clinical case report was published in the Indian Journal of Medical Microbiology (2009). Chandy et al. described a 46-year-old quarry worker from South India presenting with fever, abdominal pain, jaundice, thrombocytopenia, and renal dysfunction. Seroconversion and rising anti-hantavirus IgG titers confirmed hantavirus infection. The authors urged clinicians to consider hantavirus in the differential diagnosis of acute febrile illness alongside scrub typhus, leptospirosis, and dengue.

A second case report of clinical significance appeared in a peer-reviewed Indian journal, describing a 30-year-old postpartum woman diagnosed with Hantavirus Pulmonary Syndrome (HPS). This case was particularly notable because it documented hantavirus-associated acute respiratory distress syndrome (ARDS) and multi-organ dysfunction in a postpartum patient, a presentation not previously recorded in India. The authors recommended considering hantavirus in the differential diagnoses of severe respiratory illness following delivery.

Seroprevalence Studies and Tribal Population Risk

A 2012 study published in Primary Health Care Research & Development (Cambridge University Press) screened 72 members of the Irula tribal community of Marakkanam, Tamil Nadu. The Irulas are traditional rodent hunters whose occupation puts them in direct contact with rodents in open fields. The study detected a hantavirus seroprevalence of 6.9%, attributing this to occupational exposure to rodents.

A 2009 retrospective serotyping study at CMC Vellore (funded by ICMR) employed a serotyping ELISA to classify archived IgG-reactive samples. The study found evidence of Seoul virus (SEOV), Hantaan virus (HTNV), and Thailand virus (THAIV) in Indian patient samples, establishing that multiple hantavirus serotypes are circulating in India.

A summary of key seroprevalence data from India:

Sources: Chandy et al., Indian J Med Res, 2005; Chandy et al., Indian J Med Microbiol, 2009; Chandy et al., Trans R Soc Trop Med Hyg, 2009; Cambridge Core, 2012.

A 2008 serological and molecular survey of rodents from South India (published in International Journal of Infectious Diseases) studied 54 rodents including Rattus rattus, Bandicota species, and Mus musculus. This provided the first confirmation of an animal reservoir for hantaviruses in the Indian region, closing a critical scientific loop.

Hantavirus Strains Detected or Suspected in India

Source: Chandy et al., 2005, 2008, 2009; Carey et al., 1971; Frontiers in Microbiology, 2023.

India's Surveillance Gaps: The Silent Burden

The Integrated Disease Surveillance Programme (IDSP), managed by the National Centre for Disease Control (NCDC), is India's primary public health surveillance backbone. While IDSP effectively monitors outbreaks of dengue, leptospirosis, and scrub typhus, hantavirus is not routinely included in standard surveillance panels, and diagnostic confirmatory capacity remains largely limited to a few academic research institutions.

ICMR's Virus Research and Diagnostic Laboratory Network (VRDLN), which has expanded to 165 laboratories across 29 states and union territories since 2013, is a critical asset. However, hantavirus-specific PCR diagnostics and serological assays are not universally deployed across this network, creating significant gaps in case detection, particularly in rural and tribal belt regions where rodent exposure is highest.

"Study of hantavirus infections in India is in its early stages. As early symptoms of hantavirus disease can be non-specific and the diagnosis confirmed only by laboratory testing, use of appropriate diagnostic tools is important." — Chandy S. et al., Indian Journal of Medical Microbiology, 2009

India's high-risk zones for hantavirus transmission include agricultural and tribal communities in Tamil Nadu, Kerala, Karnataka, West Bengal, and Assam, where rodent population density is high, and occupational exposure is routine. The absence of genomic epidemiological data from these regions represents a critical knowledge gap for pharma innovators and public health planners alike.

Clinical Presentation: Recognizing Hantavirus in the Indian Context

In India, the dominant risk is HFRS from Old World strains (Hantaan, Seoul, Thottapalayam). The clinical spectrum ranges from subclinical infection to severe renal failure, with the Indian published case exhibiting fever, abdominal pain, jaundice, thrombocytopenia, and renal dysfunction.

If the Andes virus were ever introduced through travel (as potentially demonstrated by the 2026 MV Hondius outbreak), clinicians would need to consider Hantavirus Pulmonary Syndrome (HPS), characterised by fever, myalgia, headache, rapid progression to pneumonia, acute respiratory distress syndrome (ARDS), and hypotension. Symptom onset typically occurs 2 to 4 weeks after exposure.

The WHO notes that early supportive care and prompt admission to an ICU with complete facilities can materially improve survival. There are currently no approved antiviral treatments or vaccines for hantavirus infection worldwide, making early recognition and symptom management the cornerstone of clinical management.

Frequently Asked Questions (FAQs)

Q1. Is Hantavirus present in India?

Yes. Multiple seroprevalence and serotyping studies confirm that hantavirus infection has occurred in human populations in India, primarily in South India. The Thottapalayam virus, indigenous to India since 1964, Seoul, Hantaan, and Thailand strains have all been detected serologically. However, no large-scale outbreak has been documented in India to date.

Q2. How does Hantavirus spread, and can it transmit person-to-person in India?

In India, hantavirus is transmitted via inhalation of aerosolized excreta (urine, feces, saliva) from infected rodents such as Rattus rattus, Bandicota species, and Suncus murinus. The strains circulating in India (Thottapalayam, Seoul and Hantaan) are not known to be transmitted from person to person. Human-to-human transmission has been documented only for the Andes strain, which is currently not endemic in India.

Q3. Who is at the highest risk of Hantavirus infection in India?

High-risk groups include tribal communities (particularly rodent-hunting groups like the Irulas of Tamil Nadu), agricultural workers, forestry workers, rural health workers, and anyone with regular contact with rodent habitats. Studies show seroprevalence of 5.2% to 6.9% in such at-risk cohorts.

Q4. Is India at risk from the 2026 MV Hondius hantavirus cruise ship outbreak?

As of May 2026, India has not reported any confirmed cases linked to the MV Hondius outbreak. The WHO has assessed the global risk from this event as low. Travellers returning from Argentina, Chile, Uruguay, or other South American countries with rodent exposure should be monitored for symptoms (fever, myalgia, rapid respiratory deterioration) for up to 8 weeks post-exposure.

Q5. Are there treatments or vaccines for Hantavirus available in India?

Currently, there is no approved specific antiviral treatment or vaccine for hantavirus infections anywhere in the world, including India. Management is supportive, including careful fluid and electrolyte management, respiratory and hemodynamic support, and renal replacement therapy if required. Early ICU referral is the most evidence-backed intervention for improving survival outcomes.